KROS news

Nauticus Robotics, Inc. agreed to reduce the conversion price on its senior secured term loans to $1.488 for a limited period, a move subject to lender approval to maintain borrower liquidity.

Keros Therapeutics announced it will receive a $20 million development milestone payment from partner Takeda following the first patient dosing in the Phase 3 ELRiSE MF trial. This payment brings total deal value to $220 million and is subject to a 25% stockholder distribution.

Keros Therapeutics has dosed the first patient in a Phase 2 trial of Rinvatercept targeting Duchenne muscular dystrophy. As a clinical-stage biopharmaceutical company with no current drug products on the market, this trial initiation is a significant milestone for its neuromuscular development strat…

Keros Therapeutics authorized a $5 million share repurchase program following a $20 million milestone payment from Takeda. The board grants management flexibility for open-market stock buybacks.

Keros Therapeutics initiated a Phase 2 trial for rinvatercept in Duchenne muscular dystrophy and reported a Q2 net loss of $28.7 million, with cash expected to fund operations through mid-2028. The company reported a 48% decrease in operating costs due to restructuring.

Nauticus Robotics entered an exchange agreement to swap existing secured term loans for Series C preferred stock. This debt-for-equity transaction aims to restructure the company's liabilities and simplify its capital structure.

Keros Therapeutics announced the appointment of Anne Prener to its board of directors. This leadership change is expected to strengthen the company's clinical expertise as it continues advancing its therapy pipeline.

Keros Therapeutics President and CEO Jasbir Seehra will participate in a fireside chat at the Goldman Sachs 47th Annual Global Healthcare Conference on June 8, 2026. The presentation will be webcast live and archived for investor access.